LEXEO THERAPEUTICS INC (LXEO) Stock Fundamental Analysis

NASDAQ:LXEO • US52886X1072

6.57 USD
-0.22 (-3.24%)
At close: Feb 12, 2026
6.57 USD
0 (0%)
After Hours: 2/12/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

LXEO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. The financial health of LXEO is average, but there are quite some concerns on its profitability. LXEO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • LXEO had negative earnings in the past year.
  • In the past year LXEO has reported a negative cash flow from operations.
  • In the past 5 years LXEO always reported negative net income.
  • LXEO had a negative operating cash flow in each of the past 5 years.
LXEO Yearly Net Income VS EBIT VS OCF VS FCFLXEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of LXEO (-72.97%) is worse than 64.05% of its industry peers.
  • LXEO has a Return On Equity of -86.87%. This is comparable to the rest of the industry: LXEO outperforms 49.90% of its industry peers.
Industry RankSector Rank
ROA -72.97%
ROE -86.87%
ROIC N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
LXEO Yearly ROA, ROE, ROICLXEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LXEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LXEO Yearly Profit, Operating, Gross MarginsLXEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The number of shares outstanding for LXEO has been increased compared to 1 year ago.
  • The debt/assets ratio for LXEO has been reduced compared to a year ago.
LXEO Yearly Shares OutstandingLXEO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
LXEO Yearly Total Debt VS Total AssetsLXEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • An Altman-Z score of 7.32 indicates that LXEO is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 7.32, LXEO is doing good in the industry, outperforming 77.82% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that LXEO is not too dependend on debt financing.
  • LXEO has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: LXEO outperforms 48.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.32
ROIC/WACCN/A
WACCN/A
LXEO Yearly LT Debt VS Equity VS FCFLXEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 7.40 indicates that LXEO has no problem at all paying its short term obligations.
  • LXEO has a Current ratio of 7.40. This is in the better half of the industry: LXEO outperforms 72.28% of its industry peers.
  • LXEO has a Quick Ratio of 7.40. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
  • LXEO has a better Quick ratio (7.40) than 72.47% of its industry peers.
Industry RankSector Rank
Current Ratio 7.4
Quick Ratio 7.4
LXEO Yearly Current Assets VS Current LiabilitesLXEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • LXEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.29%, which is quite good.
EPS 1Y (TTM)14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, LXEO will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.60% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.72%
EPS Next 2Y22.34%
EPS Next 3Y15.91%
EPS Next 5Y15.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LXEO Yearly Revenue VS EstimatesLXEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
LXEO Yearly EPS VS EstimatesLXEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LXEO. In the last year negative earnings were reported.
  • Also next year LXEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXEO Price Earnings VS Forward Price EarningsLXEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXEO Per share dataLXEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LXEO's earnings are expected to grow with 15.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.34%
EPS Next 3Y15.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for LXEO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (2/12/2026, 8:00:00 PM)

After market: 6.57 0 (0%)

6.57

-0.22 (-3.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-24
Inst Owners81.49%
Inst Owner Change3.49%
Ins Owners0.42%
Ins Owner Change7.17%
Market Cap479.54M
Revenue(TTM)N/A
Net Income(TTM)-104.97M
Analysts88.24
Price Target20.03 (204.87%)
Short Float %16.84%
Short Ratio8.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.64%
Min EPS beat(2)13.49%
Max EPS beat(2)37.78%
EPS beat(4)3
Avg EPS beat(4)8.16%
Min EPS beat(4)-23.91%
Max EPS beat(4)37.78%
EPS beat(8)5
Avg EPS beat(8)0.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.22%
PT rev (3m)-5.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.51%
EPS NY rev (1m)0.82%
EPS NY rev (3m)21.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.97
P/tB 3.97
EV/EBITDA N/A
EPS(TTM)-2.7
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0
BVpS1.66
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -72.97%
ROE -86.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.4
Quick Ratio 7.4
Altman-Z 7.32
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)146.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.92%
EPS Next Y34.72%
EPS Next 2Y22.34%
EPS Next 3Y15.91%
EPS Next 5Y15.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.66%
EBIT Next 3Y-9.58%
EBIT Next 5YN/A
FCF growth 1Y-36.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.4%
OCF growth 3YN/A
OCF growth 5YN/A

LEXEO THERAPEUTICS INC / LXEO FAQ

What is the fundamental rating for LXEO stock?

ChartMill assigns a fundamental rating of 2 / 10 to LXEO.


Can you provide the valuation status for LEXEO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to LEXEO THERAPEUTICS INC (LXEO). This can be considered as Overvalued.


What is the profitability of LXEO stock?

LEXEO THERAPEUTICS INC (LXEO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for LXEO stock?

The Earnings per Share (EPS) of LEXEO THERAPEUTICS INC (LXEO) is expected to grow by 34.72% in the next year.